See also this year's filing and all EDGAR filings for this company.
PDF Report 0000316253_2024_ENZO_Biochem_INC.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.4577164647824136, 'aggregate_val': 58020000, 'exp_sum': 106992000, 'exp_to_value': {'LaborExpense': 0, 'CostOfGoodsAndServicesSold': 17866000, 'GeneralAndAdministrativeExpense': 27202000, 'GoodwillImpairmentLoss': 0, 'OperatingCostsAndExpenses': 55797000, 'DepreciationDepletionAndAmortization': 0, 'SellingAndMarketingExpense': 0, 'ResearchAndDevelopmentExpense': 3904000, 'remainder_Expenses': 2223000}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0000316253, ENZO Biochem INC
| xvar | xval | |
|---|---|---|
| 0 | IntangibleAssets | 0 |
| 1 | AssetsNonCurrent | 9,371,000 |
| 2 | AssetsCurrent | 98,456,000 |
| 3 | PropertyPlantAndEquipment | 13,086,000 |
| 4 | remainder_Assets | 967,000 |
| 5 | LongTermLiabilities | 3,429,000 |
| 6 | LiabilitiesCurrent | 39,989,000 |
| 7 | remainder_Liabilities | 0 |
| 8 | LaborExpense | 0 |
| 9 | CostOfGoodsAndServicesSold | 17,866,000 |
| 10 | GeneralAndAdministrativeExpense | 27,202,000 |
| 11 | GoodwillImpairmentLoss | 0 |
| 12 | OperatingCostsAndExpenses | 55,797,000 |
| 13 | DepreciationDepletionAndAmortization | 0 |
| 14 | SellingAndMarketingExpense | 0 |
| 15 | ResearchAndDevelopmentExpense | 3,904,000 |
| 16 | remainder_Expenses | -46,749,000 |
| 17 | remainder_Revenues | 31,061,000 |
| 18 | remainder_NetIncome | 47,247,000 |
| 19 | remainder_ComprehensiveNetIncome | -1,273,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 121,880,000 |
| 1 | Liabilities | 43,418,000 |
| 2 | Expenses | 58,020,000 |
| 3 | Revenues | 31,061,000 |
| 4 | StockholdersEquity | 78,462,000 |
| 5 | NetIncome | 20,288,000 |
| 6 | ComprehensiveNetIncome | 19,015,000 |
| 7 | BaseVar | 151,449,500 |
| 8 | EconomicCapitalRatio | 2.87 |